Glenmark signs cancer drug licensing deal with Hengrui Pharma for $18 million upfront payment
Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
Sessions will cover process mapping, cost optimisation, data-driven decision-making, cybersecurity, and sustainable manufacturing practices
The goal is to deliver greater value to customers, doctors, and the broader healthcare ecosystem
Pete Pharma will leverage FABRX’s extensive foundation of scientific validation to deliver a commercially viable, pharmacy-ready solution in the US
The inspection was carried out between May 26, 2025 and May 31, 2025
This approval follows the CDE’s clearance in July of this year for Phase 2/3 clinical studies of CB03-154 in amyotrophic lateral sclerosis
Alembic receives EIR from USFDA for facility at Panelav
The products include high-quality, advanced anti-infective formulations such as EMROK (Levonadifloxacin) and MIQNAF (Nafithromycin)
Subscribe To Our Newsletter & Stay Updated